PBF 999
Huntington Disease
Palobiofarma SLSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
23 Active assets in the Huntington Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deutetrabenazine Teva Branded Pharmaceutical Products R&D LLC | Phase 4 | BBB |
Tetrabenazine William Ondo, MD | Phase 4 | BBB |
ro7234292 Hoffmann-La Roche | Phase 3 | BBB |
Pridopidine Prilenia | Phase 3 | BB |
Namenda University of British Columbia | Phase 4 | BB |
View all 50 →
Same molecule, other indications
PBF 999 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →